Clarinol CLA claims hold up
This article was originally published in The Tan Sheet
Executive SummaryClaims featured in print ads and on packaging for dietary supplement Clarinol CLA have been substantiated by Soft Gel Technologies and Optio Health Products after an inquiry from the National Advertising Division. The Council for Better Business Bureaus group Oct. 6 says as part of an ongoing initiative with the Council for Responsible Nutrition, it examined Clarinol claims including: "Assists in reducing body fat and maintaining lean muscle tissue for healthy body composition" and "the clinical results show enhanced fat burning, lean muscle retention and promotion of optimal" body mass index. The watchdog group examined clinical studies as well as one study on the actual Clarinol conjugated linoleic acid product and "determined that the studies followed sound methodologies and produced statistically significant results demonstrating a reduction in body fat mass, BMI, waist, waist-to-hip ratio and fat mass around the legs and abdomen, as well as an increase in lean mass," NAD says
You may also be interested in...
Three companies are set to learn this week whether the European Medicines Agency will fast track its review of their soon-to-be-filed EU marketing applications.
As Celltrion Healthcare prepares to roll out Remsima SC, its subcutaneous infliximab, in Europe – starting in the UK and Germany – Celltrion Healthcare’s UK commercial head, Matthew Eddleston, speaks to Generics Bulletin about how the innovative biosimilar will be positioned in the market.
A trio of legislative proposals to lower high-cost “surprise” medical bills that limit what physicians and hospitals, labs, and imaging facilities can charge patients, emerged this winter from three different US congressional committees with health care jurisdiction. Check out our detailed chart that sorts out some of the provisions of the bills of interest to device and diagnostics firms.